Targeted Next Generation Sequencing and Intellectual Disability

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-31

Study Completion Date

2017-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to determine the benefit of next generation sequencing (NGS) targeted on genes involved in intellectual disability for etiologic diagnosis of intellectual disabilities. In other words, it concerns the number of patients whose etiologic diagnosis will be established with NGS and could not with common techniques. Actually, the molecular etiology of intellectual disability is crucial to calculate the risk of recurrence and allows the perinatal diagnosis to these families.

Secondary purposes are:

1. To determine the place of NGS in the strategy of etiologic diagnosis of intellectual disability, to determine the order of analyses performed for a patient with intellectual disability without clinical signs.
2. To evaluate the number of variants with unknown significance and thus non-usable for genetic counselling without supplementary analysis.
3. To determine the number of samples that can be at most pooled keeping a good efficacy of capture and results with suitable read depth
4. To determine the possibility of detecting copy number variations (CNVs) in genes of interest with NGS
5. To establish genotype/phenotype correlations for each gene for which a mutation has been identified
6. To optimize the software pipelining for a rapid analysis for diagnosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Various Type of Genetic Events in Patients With Intellectual Disability

NCT02881333

Intellectual Disability

UNKNOWN

Contribution of High Throughput RNA Sequencing Combined With Sequencing of Whole Genomes in the Diagnosis of Intellectual Disability

NCT03857997

Patients With Intellectual Disabilities Without an Obvious Clinical Diagnosis Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)

COMPLETED

Medico-economic Evaluation of Different High-throughput Sequencing Strategies in the Diagnosis of Patients With Intellectual Deficiency

NCT03287206

Intellectual Deficiency

COMPLETED

Genome Sequencing Strategies for Genetics Diagnosis of Patients With Intellectual Disability

NCT04154891

Intellectual Disability

COMPLETED NA

Search for Phenotype-modifying Genes in Patients With Intellectual Disabilities.

NCT06706934

Intellectual Disability

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intellectual Disability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intellectual disability

Blood sample

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate or severe intellectual disability
* Availability of patient and parent DNA
* No etiologic diagnosis with standard approaches: negative fragile X, normal pangenomic 180K and 1M array-CGH
* Informed consent of person having parental authority